[Efficiency and safety of ACE-inhibiting imidapril in patients with essential hypertension].
In: Acta medica Austriaca, Jg. 29 (2002), Heft 2, S. 72-6
Online
academicJournal
Zugriff:
In a survey including 2224 patients with essential hypertension we investigated efficacy and tolerability of the new ACE-inhibitor Imidapril. Mean blood pressure at baseline was 172 +/- 19/98 +/- 10 mmHg. Treatment with Imidapril 5-20 mg once daily caused a decrease in BP by 21 +/- 17/11 +/- 10 mmHg (p < 0.01/0.01). Systolic BP was reduced by > 15 mmHg in 71% diastolic BP by > 10 mmHg in 64% of patients. 29% of patients achieved the treatment goal of a blood pressure < or = 140/90 within an average of 26 days. Imidapril decreased pulse-pressure (one of the most important risk markers in hypertension) by 18% (74 +/- 17 to 61 +/- 11 mmHg, p < 0.01). ACE-inhibitor related adverse effects (cough, vertigo, headache, pruritus, tachycardia, orthostatic dysregulation or nausea) were observed in 38 patients (< 2%). Efficacy of treatment was graded by the physician in charge of the patient care by means of a questionnaire. Gradings were excellent or good in 96% of patients, moderate in 3% and poor in < 1%. In summary, the effects of Imidapril on blood pressure were comparable to those of other ACE-inhibitors. However, the frequency of adverse effects was low and similar to that of angiotensin-II-antagonists.
Titel: |
[Efficiency and safety of ACE-inhibiting imidapril in patients with essential hypertension].
|
---|---|
Autor/in / Beteiligte Person: | Zweiker, R ; Stoschitzky, K ; Maier, R ; Klein, W |
Link: | |
Zeitschrift: | Acta medica Austriaca, Jg. 29 (2002), Heft 2, S. 72-6 |
Veröffentlichung: | 2003- : Wien : Springer Verlag ; <i>Original Publication</i>: Wien, Hollinek., 2002 |
Medientyp: | academicJournal |
ISSN: | 0303-8173 (print) |
DOI: | 10.1046/j.1563-2571.2002.02007.x |
Schlagwort: |
|
Sonstiges: |
|